Suppression of the Hypoxia-Inducible Factor-1 Response in Cervical Carcinoma Xenografts by Proteasome Inhibitors

Diana C. Birlé1 and David W. Hedley1,2

1Division of Applied Molecular Oncology, Ontario Cancer Institute and 2Departments of Medical Oncology and Hematology, Princess Margaret Hospital and University of Toronto, Toronto, Ontario, Canada

Abstract

Experimental data suggest therapeutic advantage from selective disruption of the hypoxia response. We recently found that the proteasome inhibitor bortezomib decreases tumor carbonic anhydrase IX (CAIX) expression in colon cancer patients and herein report a companion laboratory study to test if this effect was the result of hypoxia-inducible factor (HIF) inhibition. Human cervical (SiHa and Me180) and colon (RKO) carcinoma cell lines were treated with bortezomib or the structurally unrelated proteasome inhibitor MG132 in normoxic and hypoxic conditions in vitro. Two different in vivo experiments investigated bortezomib effects after single dose (2 mg/kg, 24 h) or longer exposure in severe combined immunodeficient mice bearing SiHa xenografts. Treatment with either drug produced accumulation of HIF-1α in vitro but strongly inhibited the production of CAIX and vascular endothelial growth factor (VEGF) under hypoxia. This correlated with more than 10-fold reduction in HIF-1 transcriptional activity under hypoxic conditions. A similar effect of bortezomib was seen in vivo, using the nitroimidazole probe EF5 to define regions of tumor hypoxia and a triple immunofluorescence technique to measure the spatial distributions of HIF-1α and CAIX. Plasma VEGF levels decreased by ~90% during treatment with bortezomib, indicating that this agent can potentially inhibit the hypoxia response in tumors. [Cancer Res 2007;67(4):1735–43]

Introduction

The 26S proteasome is involved in the disassembly of proteins that have been targeted by ubiquitin ligases. In addition to the disposal of proteins that are defective, due for example to misfolding, the ubiquitin ligase/proteasomal system plays an active role in regulating the levels of proteins involved in the control of cell processes, including the regulation of the cell cycle and several transcription factors (1). Because the turnover of many of these proteins in cancers is different from that seen in normal tissues, its disruption by proteasomal degradation (4, 5). The proline hydroxylases (PHD) are HIF-1α subunit undergoes proline hydroxylation at Pro402 and Pro564 that is recognized by von Hippel-Lindau (VHL)–dependent ubiquitin ligases and targeted for proteasomal degradation (4, 5). The proline hydroxylases (PHD) are suppressed under hypoxia, allowing accumulation of HIF-1α, which then associates with its dimerization partner HIF-1β to form the HIF-1 transcription factor. Several transcriptional targets are activated by HIF-1 that in aggregate promote survival under hypoxic conditions. These include enzymes involved in glucose uptake and metabolism, carbonic anhydrase IX (CAIX) that plays a role in the buffering of acidic products of glycolysis, erythropoietin, and vascular endothelial growth factor (VEGF; ref. 6).

It has been shown previously that proteasome inhibition results in the accumulation of HIF-1α in tissue culture under aerobic conditions, although in at least some experimental systems, this is not able to form transcriptionally active HIF-1 heterodimers (7, 8). Nevertheless, because HIF-1 activation promotes cancer cell survival in regions of tumor hypoxia, we considered that HIF-1α accumulation during bortezomib treatment might be a useful biomarker for pharmacodynamic effects in cancer patients. This was tested in a phase II clinical trial of bortezomib in patients with chemotherapy-refractory colorectal cancer metastatic to liver, conducted by the Princess Margaret Hospital Phase II Consortium and reported elsewhere (9). As part of that trial, patients consented to image-guided core biopsies from liver metastases at baseline and after 1 week of treatment with bortezomib. Parallel tissue sections were stained by immunohistochemistry for HIF-1α and the HIF-1 transcriptional product CAIX, and the extent of staining was quantified by digital image analysis of the viable tumor tissue. Unexpectedly, we found a highly significant decrease in the amount of CAIX expression in relation to HIF-1α as well as an overall increase in HIF-1α and decrease in CAIX following treatment with bortezomib.
bortezomib, suggesting that in addition to the anticipated increase in HIF-1α, the production of CAIX in hypoxic regions of colon cancer was being disrupted by bortezomib. The possibility that bortezomib was acting to inhibit HIF-1 activity under hypoxic conditions was therefore tested in a companion laboratory study that forms the basis of the present report.

Materials and Methods

Reagents and antibodies. Bortezomib (formerly known as PS341) was obtained from Millenium Pharmaceuticals, Inc. (Cambridge, MA), and MG132 was purchased from Calbiochem (San Diego, CA). Bortezomib used for tissue culture and MG132 were both dissolved in DMSO, aliquoted, and stored at −20°C. The antibodies used were against HIF-1α (BD Biosciences, Mississauga, Ontario, Canada), α-tubulin (Oncogene, Cambridge, MA), β-actin (Abcam, Inc., Cambridge, MA), cleaved caspase-3 (Cell Signaling Technology, Beverly, MA), FIH-1 (Novus Biologicals, Inc., Littleton, CO), p21 (Calbiochem, EMD Biosciences, Inc., San Diego, CA), p53 (Santa Cruz Biotechnology, Inc., Santa Cruz, CA), p84 (Genetex, Inc., San Antonio, TX), and p300 (NH2 terminus; Santa Cruz Biotechnology), whereas 4,6-diamidino-2-phenylindole (DAPI) was from Roche Diagnostics (Manheim, Germany). Anti-CAIX and anti-Pro564-HIF-1α antibodies (10, 11) were kind gifts from Dr. A. Harris (University of Oxford, Oxford, United Kingdom), whereas anti-EF5 was from Dr. Cameron Koch (University of Pennsylvania, Philadelphia, PA). The secondary antibodies for indirect immunofluorescence staining were Cy3-conjugated donkey anti-rabbit and Cy5-conjugated antimouse (Jackson ImmunoResearch, West Grove, PA), whereas the ones used for Western blots (antimouse and antirabbit IgG antibodies) were from Amersham Biosciences (Buckinghamshire, United Kingdom). Protein G-Sepharose was from Sigma-Aldrich Canada Ltd. (Oakville, Ontario, Canada).

Cell culture. The human cervical squamous cell carcinoma SiHa and Me180, colon carcinoma RKO, and prostate carcinoma PC3 cell lines were obtained from American Type Culture Collection (Manassas, VA). SiHa was grown in α-MEM, Me180 in McCoy’s medium, RKO in Ham’s F-12:DMEM H21 1:1, and PC3 in Ham’s F-12 medium. All the media for cell culture were supplemented with 10% fetal bovine serum, and cells were grown at 37°C and 5% CO2 in air, unless otherwise specified.

Cell treatment, cellular fractionation, immunoprecipitation, and immunoblotting. Cells grown at 60% to 70% confluence were treated with proteasome inhibitors and exposed to normal atmosphere (21% O2, 5% CO2, balance air) or low (0.2% O2, 5% CO2, balance nitrogen) O2 concentrations (aerobic conditions) was done on SiHa cells. Cell treatment, cellular fractionation, immunoprecipitation, and nuclear fraction (30 min of balance air) or low (0.2% O2, 5% CO2, balance nitrogen) O2 concentrations was therefore tested in a companion laboratory study.

Luciferase assays. The constructs used for cotransfections were kind gifts from other laboratories: 5× hypoxia response element (HRE)-luciferase (5× HRE-luc) from Dr. A. Giaccia (Stanford University, Stanford, CA), and the control plasmid lacking the HREs cytomegalovirus-luciferase (CMV-luc) from Dr. R. Hill (University of Toronto, Toronto, Ontario, Canada). The pcDNA3.1/His/LacZ was obtained from Invitrogen (Carlsbad, CA). Transfection was done using Fugene 6 (Promega, Madison, WI) according to the manufacturer’s instructions. On the 2nd day, after cotransfections, cells were reseeded, and the next day, drug treatment together with exposure to normoxic or hypoxic conditions began. After 24 h of treatment, cells were lysed, and the luciferase assay was completed according to the manufacturer’s instructions (Dual-Light System, A&B Biosciences, Bedford, MA). The results were normalized to the values read for β-galactosidase activity. The luminometer used was Luminoskan Ascent (ThermoLab Systems, Franklin, MA).

SiHa xenografts. Animal experiments were done in the Animal Facility of the Princess Margaret Hospital, operated under the guidelines approved by the Canadian Council for Animal Care. SiHa cell suspension (0.1 mL containing approximately 5 × 10⁶ cells) was injected into the left gastrocnemius muscle of severe combined immunodeficient (SCID) mice. After ~3 weeks, the tumors became readily visible and the tumor + leg diameter measured between 10 to 11 mm (tumor mass, ~0.4 g). The clinical formulation of bortezomib, made up freshly each day, was used for these experiments. Two in vivo experiments were done: one to investigate the acute effect of bortezomib (2 mg/kg i.p. single dose) and another one to assess the effects of a prolonged treatment (up to three doses of 1.5 mg/kg i.p. every other day). In the first experiment, 8 mice were randomly assigned to bortezomib or drug vehicle control, whereas in the second, 20 mice were assigned to four groups: single dose, two doses, and three doses of bortezomib or three doses for vehicle control. Mice were killed 24 h after the last treatment, blood samples were obtained by cardiac puncture, and the tumors were excised. Four hours before killing, the nitroimidazole hypoxia probe EF5 was injected both i.p. and i.v. Each tumor was dissected from the surrounding tissues and cut into several slices: some were snap frozen in liquid nitrogen, and the rest were fixed in formalin for 24 h and paraffin embedded. The blood was collected in heparin-coated syringes and centrifuged at low speed, and the supernatant was frozen at −70°C. The VEGF ELISA assay was done according to the manufacturer’s instructions (R&D Systems, Minneapolis, MN). This kit recognizes both human VEGF165 and VEGF121 and at 50 ng/mL does not cross-react with mouse VEGF.

Immunofluorescence staining. Serial sections were cut from ornithine carbamyl transferase–embedded tumor tissue: one of them was stained with H&E for transmitted light microscopy and used for selecting the tumoral areas, on which the further image analysis was to be done. The other sections were multiple labeled for the following: (a) HIF-1α, CAIX, and EF5 and (b) HIF-1α and cleaved caspase-3. Secondary antibodies used alone were control for nonspecific background. All sections were counterstained with DAPI 1 μg/mL to outline the nuclear area. Measurements of stained area were made only in the viable tumor areas excluding necrotic or non tumoral tissue.

Computerized image analysis. Tissue sections were examined using a Microcomputer Imaging Device image analysis system (Imaging Research, Inc., St. Catharines, Ontario, Canada) equipped with a Quantix cooled CCD camera (Photometrics, Tucson, AZ) mounted on an Olympus BX50 epifluorescence microscope. The analysis included the entire viable tumoral area identified on the slide, using a scanning autostage to create composite images of individual fields at ×20 magnification as described previously (12). A tumoral map that included only viable tumor was made using the H&E sections and then carefully adjusted on the composite DAPI images. The final image analysis was done using in-house developed software written in IDL 6.1 (Research Systems, Inc., Boulder, CO). For the 12-bit grayscale images, the threshold was set individually at a brightness level that best separated the signal from the background. For each marker, we measured the percentage of positive stained area, based on the threshold images. Only the part of the image that corresponded to the tumoral map was analyzed.
Results

In vitro Experiments

Effects of proteasome inhibitors on accumulation of HIF-1α and inhibition of CAIX and VEGF expression during hypoxia. SiHa and Me180 (cervical carcinoma cell lines) and RKO (colon carcinoma) were treated for 24 h with bortezomib or the structurally unrelated proteasome inhibitor MG132 and exposed during this interval to either normal (21%) or low (0.2%) oxygen concentrations. Whole lysates were used for Western blotting (Fig. 1A and B, SiHa; C, Me180; and D, RKO), whereas secreted VEGF levels were measured in the medium collected from the SiHa-treated samples (Fig. 1E). Bortezomib and MG132 protected the HIF-1α subunit from proteasome degradation and, as expected, the protein accumulated in aerobic as well as in hypoxic conditions. Concurrently, the expression of CAIX and VEGF, which is HIF dependent, was suppressed under hypoxia. The increased expression of HIF-1α under aerobic conditions was not associated with the expression of CAIX or change in VEGF levels when compared with the control, suggesting that the function of HIF-1α was impaired by the proteasome inhibitors, regardless of oxygen tension.

Proteasome inhibitors negatively affect HRE transcription. SiHa cervical carcinoma and RKO colon carcinoma cells were transfected with different luciferase constructs: either one containing five HRE inserts (5× HRE-luc) or one lacking any HRE sequence (CMV-luc) as a control for the hypoxic response and a β-galactosidase reporter to normalize the luciferase readings. The cells were treated with proteasome inhibitors for 24 h while exposed to either aerobic or hypoxic conditions. Hypoxia-induced HRE binding–dependent transcription for SiHa cells was more exposed to either aerobic or hypoxic conditions. Hypoxia-induced HRE binding–dependent transcription for SiHa cells was more than 400-fold higher in untreated cells when compared with the control, suggesting that the function of HIF-1α, consisting with the accepted role of the proteasome in hypoxic conditions, treatment of SiHa cells with bortezomib resulted in accumulation of the hydroxylated form of HIF-1α (at Pro564), consistent with the accepted role of the proteasome in HIF-1α degradation under these conditions (7). However, we also observed accumulation of hydroxylated HIF-1α at low oxygen levels that was markedly increased in the presence of proteasome inhibitors, suggesting the persistence of some PHD activity under hypoxia.

FIH-1 is another enzyme responsible for HIF-1α hydroxylation (Asn803) and also for subsequent impaired function of HIF, as this inhibits binding to the transcriptional coactivator p300 (5). To test if HIF-1α accumulated during proteasome inhibition associated with FIH-1, we did immunoprecipitation with the respective antibody on lysates from SiHa cells treated with bortezomib or MG132 for 24 h under normoxic conditions or 0.2% O2. As shown in Fig. 2B, both drugs increased the levels of HIF-1α complexed with FIH-1, and this effect was seen under hypoxic as well as aerobic conditions.

Previous studies favored cytoplasmic localization for FIH-1 (5), whereas others reported significant amount in the nucleus (15). Although we showed the presence of HIF-1α–FIH-1 complex, because HIF-1α was found mostly in the nucleus, we were interested in investigating FIH-1 access to its substrate. As shown in Fig. 2C, FIH-1 was indeed mainly cytoplasmic; however, there was also a certain nuclear amount. Of interest, exclusively in the nuclear fraction, we noticed a strong band slightly above 120 kDa. This was identified using FIH-1 antibodies from two different sources. Additionally, excessive stabilization of FIH-1 when the proteasome is inhibited or under hypoxia can be excluded because the protein level was basically constant regardless the treatment or oxygen concentrations (Fig. 2D).

Both types of hydroxylases (PHDs and FIH-1) remain active in low-oxygen conditions as was shown by our results, whereas PHDs are reported to accumulate when proteasomal degradation is inhibited (14). Hydroxylation of HIF-1α at Pro564 and Pro402 provides a much higher affinity for VHL, which ensures further ubiquitination and recruitment of corepressors, whereas hydroxylation at Asn803 impairs the binding of transcription coactivators (16–18). Thus, we considered that modification of these enzymes might explain the loss of transcription with bortezomib.

Cobalt is a well-known inhibitor of hydroxylases, and FIH-1 is reported to be more sensitive than PHDs (19). However, similar to the effects seen with hypoxia, treatment with the bortezomib and MG132 inhibited the activation of CAIX when SiHa cells were treated with 100 μmol/L CoCl2 for 24 h (Fig. 2E).

p53 and HIF-1α during proteasomal inhibition. There is an important body of literature describing the relationship between p53 and HIF-1α during hypoxia, mediated or not through Mdm2. p53 is reported to participate in HIF-1α degradation (20–23) as well as in inhibition of HIF transcriptional function through competition for the coactivator p300 (22). The cellular levels of p53 are also adjusted by the proteasome, and treatment with bortezomib or MG132 resulted in the accumulation of p53 in SiHa and Me180 cells (Fig. 3A and B). To test if p53 was transcriptionally active following treatment with proteasome inhibitors, we measured the expression of p21 following exposure to hypoxia or irradiation and found that this was not suppressed by bortezomib or MG132 (Fig. 3A and B). These results suggest that the inhibition of HIF-1α is not simply due to nonspecific effects of proteasome inhibition on transcription. Note that both of these cell lines express the E6 papilloma viral
protein that accelerates p53 degradation, and this probably accounts for the lack of p21 induction by radiation in the absence of proteasome inhibition (24).

Because p53 accumulates with proteasome inhibitors and remains functional, consistent with previous reports (24, 25), we considered that this might affect HIF transcription. We tested this using PC3, a prostate carcinoma cell line that is p53 null (26). As shown in Fig. 3C, these cells expressed CAIX under aerobic as well as hypoxic conditions, and this was suppressed by the proteasome inhibitors, suggesting that the accumulation of p53 is unlikely to explain the effects of bortezomib on HIF-1 activity.

Proteasome inhibition decreases p300 binding to HIF-1α during hypoxia. In hypoxic conditions, HIF-1 transactivation relies on the recruitment of various coactivators, including p300 that interacts with the HIF-1α COOH terminus to ensure further binding to DNA and transcriptional activation (5). It has been reported previously that DNA binding is maintained during proteasome inhibition (7). To test this, nuclear fractions from SiHa cells were immunoprecipitated with a p300 antibody directed against its NH2 terminus and probed with an anti–HIF-1α antibody. As shown in Fig. 4A, treatment with proteasome inhibitors resulted in decreased binding of HIF-1α to p300 under hypoxia (Fig. 4A), with no change in the total cellular levels of p300 (Fig. 4B).

In vivo Experiments
Effects of bortezomib on HIF-1α and CAIX in relation to tumor hypoxia. Two groups of four SCID mice bearing i.m. SiHa...
xenografts were treated with a single i.p. injection of 2 mg/kg bortezomib or vehicle control. Four hours before sacrifice, animals were treated with the nitroimidazole hypoxia probe EF5, and tumors were harvested at 24 h. As shown in Fig. 5A, HIF-1α and CAIX were strongly colocalized with EF5 in control tumors. However, 24 h after bortezomib treatment, there was increased expression of HIF-1α in EF5-negative tissue and a pronounced decrease in the level of CAIX in hypoxic regions: similar to the results seen when SiHa cells were treated with bortezomib and exposed to hypoxia in vitro (Fig. 1A). The effects on HIF-1α were analyzed by imaging the entire histologic section, manually outlining viable tumoral areas, and then obtaining the percentage of nuclear area (defined by DAPI staining) that was positively labeled for HIF-1α in EF5-negative or EF5-positive regions. As shown in Fig. 5B, treatment with bortezomib resulted in statistically significant increases in HIF-1α levels in both the total and the EF5-negative tumoral areas (P = 0.012 and P = 0.015).

The analysis of CAIX did not take into account DAPI staining because this is predominantly a surface membrane protein. As shown in Fig. 5C, bortezomib treatment resulted in highly significant decreases in CAIX levels in hypoxic regions defined by EF5 as well as in the HIF-1α–positive and the total viable tumoral areas (P < 0.001 in all cases).

**Activation of caspase-3 by bortezomib in SiHa xenografts.** Because HIF-1–dependent transcription can promote cell survival in hypoxic conditions (27), we asked if bortezomib treatment might enhance apoptosis in hypoxic regions of SiHa xenografts. A total of 20 SCID mice bearing SiHa xenografts were divided into four groups of five each and treated on alternate days with one, two, or three doses of 1.5 mg/kg bortezomib or vehicle control. Animals were injected with EF5 4 h before sacrifice, and the tumors were harvested 24 h after the last bortezomib treatment. Tissue sections were stained for EF5, HIF-1α, and cleaved caspase-3. As shown in Fig. 6, there was an overall increase in the mean percentage tumoral area of cleaved caspase-3 expression after a single dose of bortezomib (4.00 ± 0.72 SE versus 1.51 ± 0.29 SE for control).
indicates that the drug has an anticancer effect in this model, although there was no significant effect on tumor volume during the treatment period used in this experiment. This effect was seen in several human epithelial cancer cell lines and also with the structurally unrelated proteasome inhibitor MG132, suggesting that it might be a general effect of proteasome inhibition in human cancers under hypoxic conditions. Similarly, using the extrinsic nitroimidazole probe EF5 to outline hypoxic microregions of SiHa cervical carcinoma xenografts, we found accumulation of HIF-1α, together with a large decrease in CAIX in hypoxic regions following bortezomib treatment. This effect is consistent with our recent findings in colon cancer patients treated with bortezomib, where there was a significant increase in HIF-1α relative to CAIX in sequential biopsies obtained from liver metastases before and after 1 week of bortezomib (9). Moreover, treatment with bortezomib resulted in a large decrease in the plasma concentration of human VEGF in mice bearing SiHa xenografts, further supporting the idea that this agent is a potent inhibitor of the hypoxic response in solid tumors.

Discussion

In this report, we show that bortezomib suppresses the activation of HREs and the production of CAIX and VEGF under hypoxic growth conditions in vitro, with almost complete inhibition at the highest dose tested. This effect was seen in several human epithelial cancer cell lines and also with the structurally unrelated proteasome inhibitor MG132, suggesting that it might be a general effect of proteasome inhibition in human cancers under hypoxic conditions. Similarly, using the extrinsic nitroimidazole probe EF5 to outline hypoxic microregions of SiHa cervical carcinoma xenografts, we found accumulation of HIF-1α, together with a large decrease in CAIX in hypoxic regions following bortezomib treatment. This effect is consistent with our recent findings in colon cancer patients treated with bortezomib, where there was a significant increase in HIF-1α relative to CAIX in sequential biopsies obtained from liver metastases before and after 1 week of bortezomib (9). Moreover, treatment with bortezomib resulted in a large decrease in the plasma concentration of human VEGF in mice bearing SiHa xenografts, further supporting the idea that this agent is a potent inhibitor of the hypoxic response in solid tumors.

Rapid degradation of the ubiquitinated HIF-1α is considered the principal mechanism through which HIF-dependent transcription is suppressed during normoxia. Because proteasome inhibition in vitro produced accumulation of HIF-1α, this was expected to result in the transcription of hypoxia-induced genes, regardless of oxygen level, rather than the observed inhibition of HIF-1α, especially under hypoxia. Nevertheless, a "paradoxical" effect of bortezomib on the HIF pathway (28) is already mentioned in the literature, as

Figure 3. A, p53 and p21 accumulated in Me180 cells when treated with bortezomib and MG132, respectively, and exposed to either normal (21%) or low (0.2%) oxygen concentrations for 24 h. B, SiHa cells were treated with proteasome inhibitors and irradiated (10 Gy); 6 h later, the cells were collected and total lysates were used for Western blotting. C, PC3 prostate carcinoma cells (p53−/−) were treated with bortezomib and MG132, respectively, and exposed to either normoxic or hypoxic conditions for 24 h. Total lysates were used for Western blotting. All these experiments were done at least thrice. Representative results are shown.

Bortezomib suppresses plasma VEGF levels in mice bearing SiHa xenograft. Plasma levels of human VEGF were measured in animals treated with 1.5 mg/kg bortezomib, using an ELISA assay. Mean plasma VEGF in untreated control mice was 130.9 ± 31.9 pg/mL SE, and this showed a large decrease 24 h following a single dose of bortezomib, which persisted with alternate day treatment 8.8 ± 3.1 after one dose, 8.7 ± 1.2 after two doses, and 16.7 ± 9.1 after three doses (Supplementary Fig. S2). Because the tumor size was not significantly affected by the drug, this effect is most likely due to the suppressed transcription of the gene.

Figure 4. A, nuclear fractions from lysed SiHa cells treated with proteasome inhibitors in normoxic and hypoxic conditions were immunoprecipitated with anti-p300 (NH2 terminus) antibody, and the blot was probed with HIF-1α. B, Western blot of total lysates from treated SiHa cells probed with the same p300 antibody. All these experiments were done more than thrice. Representative results are shown.
several groups reported an antiangiogenic affect or enhanced apoptosis following in vivo treatment with bortezomib, alone or in combination with chemotherapeutic agents (29–31). These observations are in accord with our own findings about VEGF and caspase-3 expression in the described cervical carcinoma in vivo model.

An increasing number of studies focused recently on HIF-1α regulation by prolyl hydroxylation. The inhibition of PHDs activity due to decreased oxygen levels is considered critical for HIF-1α escaping from proteasome degradation during hypoxia because the affinity of VHL for the nonhydroxylated HIF-1α is much lower (32–37). However, this concept seems to need adjustment as an overall increase in cellular hydroxylase activity has been observed during hypoxia (38), and there is evidence for the presence of at least some PHD activities in such conditions (37, 39, 40). This is supported by the hypoxic induction of PHD2 and PHD3 transcription (33, 38, 41–43) and also by the elegant study of Appelhoff et al. (40) who showed that it is the abundance of the enzyme that dictates further the involvement of each PHD in HIF regulation. Recently described elements, such as Siah1a/2 and OS-9, might contribute also to this picture. Siah1a/2 are members of the E3 ubiquitin ligase family, efficient within a large range of O2 concentrations, which can limit PHD1/PHD3 amounts during hypoxia by mediating their proteasomal degradation (14). Ubiquitously expressed OS-9 binds to both HIF-1α and PHDs and can further enhance hydroxylases activity (44).

Consequently, it was attractive to consider prolyl-hydroxylases of importance when examining the effect of bortezomib on HIF activity. Protected from proteasomal degradation, PHDs might accumulate, particularly during hypoxia when their transcription is induced, resulting in the higher levels of hydroxylated HIF-1α shown in Fig. 2A. Hydroxylation at Pro402/Pro564 seems to be an irreversible process (39, 40) and increases pVHL affinity for HIF-1α by several orders of magnitude (17, 18, 45). This leads to further poly-ubiquitination, recruitment of transcriptional corepressors (histone deacetylases), and impaired HIF function (16).

Although HIF-1α accumulates during hypoxia, additional regulatory steps are required to fine-tune its activity. FIH-1 (the inhibiting factor of HIF-1) is an asparaginyl hydroxylase that binds to the HIF-1α–VHL complex and controls HIF-1 transactivation by obstructing the recruitment of CBP/p300 coactivators (16, 36, 46). Of interest, FIH-1 is functionally active in both aerobic and hypoxic conditions (16, 47), consistent with the coprecipitation data shown in Fig. 2B. Our data indicate also that PHDs activity and the binding of FIH-1 to HIF-1α are maintained in the presence of bortezomib, regardless of the oxygen concentration, whereas, in contrast with PHDs accumulation during proteasome inhibition (14), FIH-1 levels are not modified (Fig. 2D). Furthermore, the effects of proteasome inhibition on HIF function were similar in hypoxia and when HIF-1α was induced using cobalt. Because cobalt mimics hypoxia by inhibiting both PHDs and FIH-1 (19), we

Figure 5. Treatment of mice bearing SiHa xenografts with bortezomib results in both the accumulation of nuclear HIF-1α in nonhypoxic areas and the suppression of CAIX expression. A, representative examples of tiled images (1 mm² tumoral area at ×200 magnification) from control and bortezomib-treated mice, stained for EF5, HIF-1α, and CAIX. B, analysis of nuclear HIF-1α levels in the total viable tumor area and in nonhypoxic or hypoxic areas defined by EF5 staining (Pα = 0.012 and Pβ = 0.005). C, effects of bortezomib on CAIX staining in the total viable tumor area and in areas defined by either EF5 or HIF-1α staining (P < 0.001 in all cases). Columns, mean of five tumors in each group; bars, SE. a and b, statistical significance when compared with the control. Results from this experiment were shown in McKay et al. (9).
regulation of HIF-1 transcription by proteasome inhibitors. These results are optimal for ARD1, critical for HIF-1α binding by VHL (47), whereas a hypoxic environment ensures the activity of thioredoxin, which contributes to HIF-1 transactivation together with Ref-1 (49).

At the present time, the mechanism by which proteasome inhibitors suppress the response to hypoxia remains unclear. Based on our results, we can conclude that this is a specific effect toward HIF-1α and exclude prolyl and asparaginyl hydroxylases as well as p53 as determinant factors. Nevertheless, alterations involving other molecules that interact with HIF-1α, whether they are positive or negative regulators, or conformational modifications of HIF-1α molecule itself, could lead to this outcome, as we were able to show lower binding of the p300 transcriptional coactivator.

It should be noted that shortly after this article was submitted, Kaluz et al. (50) also reported that bortezomib disrupts the transcriptional activity of HIF-1α via specific effects on the COOH-terminal activation domain and that this effect was relieved by overexpressing p300. Unlike our findings, these authors were not able to show decreased p300 binding following proteasome inhibition. However, because our own immunoprecipitation data (Fig. 4) show only partial loss of HIF-1α binding, which might be explained by differences in experimental technique, we would agree with Kaluz et al. that the direct inhibition of p300 interaction is not sufficient to explain the profound loss of HIF-1α transcriptional activity under proteasome inhibition.

Tumor hypoxia is an adverse prognostic feature in human cancers, and hypoxic tumors are less sensitive to cancer treatments, such as chemotherapy and radiation. Experimental results suggest that agents targeting HIF-1 might be selectively toxic to hypoxic tumor tissue and therefore enhance the effects of conventional therapy. Together with the recent article by Kaluz et al. (50), we believe that the results shown here provide a mechanistic explanation for our earlier empirical finding that bortezomib treatment disrupts the hypoxia response in the liver metastases of colorectal cancer patients (9). Further investigation of an anti–HIF-1 role for bortezomib, and probably other proteasome inhibitors, should include preclinical testing of combinations with radiation treatment and additional pharmacodynamic measurements, such as plasma VEGF levels, aimed to detect HIF-1 inhibition effects in human clinical trials.

**Acknowledgments**

Received 7/21/2006; revised 11/24/2006; accepted 12/5/2006.

Grant support: National Cancer Institute of Canada using funds raised by the Terry Fox Run.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

We thank Andrew Morrisson, May Cheung, and Pinjiang Cao for excellent technical help and Dr. Richard Hill for his critical comments.

**References**


10. Knowles HJ, Mole DR, Batchliff PJ, Harris AL. Normoxic stabilization of hypoxia-inducible factor-1α by modulation of the labile iron pool in differentiating...


33. Berra E, Benizri E, Ginosovs A, Volmat V, Roux D, Pouyssegur J. HIF-prolyl-hydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF-1α in normoxia. EMBO J 2003;22:4802–90.


42. Kaluz S, Kaluzova M, Stanbridge EJ. Proteasomal inhibition attenuates transcriptional activity of hypoxia-inducible factor 1 (HIF-1α) via specific effect on the HIF-1α C-terminal activation domain. Mol Cell Biol 2006;26:5895–907.
Suppression of the Hypoxia-Inducible Factor-1 Response in Cervical Carcinoma Xenografts by Proteasome Inhibitors

Diana C. Birle and David W. Hedley


Updated version
Access the most recent version of this article at:
http://cancerres.aacrjournals.org/content/67/4/1735

Supplementary Material
Access the most recent supplemental material at:
http://cancerres.aacrjournals.org/content/suppl/2007/02/13/67.4.1735.DC1

Cited articles
This article cites 50 articles, 25 of which you can access for free at:
http://cancerres.aacrjournals.org/content/67/4/1735.full.html#ref-list-1

Citing articles
This article has been cited by 8 HighWire-hosted articles. Access the articles at:
/content/67/4/1735.full.html#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.